Perrigo to divest HRA Pharma Rare Diseases business to Esteve for €275m
The binding offer consists of an upfront cash payment of €190m and up to €85m in potential earnout…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
26 Apr 24
The binding offer consists of an upfront cash payment of €190m and up to €85m in potential earnout…
24 Apr 24
The deal includes EP262, a first-in-class, potent, highly selective, once-daily small molecule MRGPRX2 antagonist, and EP547, a first-in-class…
03 Apr 24
Under the deal, Genmab will gain global rights to ProfoundBio’s portfolio of next-generation ADCs which consists of three…
26 Mar 24
The acquisition is expected to advance Nuvation Bio as a late-stage, international oncology firm in which its current…
26 Mar 24
Through the deal, the American pharma major gains access to NX-13, Landos Biopharma’s flagship asset, which is being…
22 Mar 24
LENZ Therapeutics to debut on Nasdaq under the ticker symbol “LENZ” as a publicly traded company advancing late…
14 Mar 24
Under the agreement, Novartis made fixed payments to fully fund IFM Due’s research and development expenses for the…
12 Mar 24
The asset sale consists of the majority of the company's workforce and most of its clinical equipment and…
23 Feb 24
Blueprint Medicines will be paid a purchase price of $15m, of which $10m is due upon Rigel's first…
22 Feb 24
The deal is expected to enable Dario to create a complete digital offering in the market for chronic…